435 related articles for article (PubMed ID: 35972597)
21. Histone deacetylases: a saga of perturbed acetylation homeostasis in cancer.
Parbin S; Kar S; Shilpi A; Sengupta D; Deb M; Rath SK; Patra SK
J Histochem Cytochem; 2014 Jan; 62(1):11-33. PubMed ID: 24051359
[TBL] [Abstract][Full Text] [Related]
22. Histone Deacetylase Inhibitors in Cancer Therapy.
Sun Y; Sun Y; Yue S; Wang Y; Lu F
Curr Top Med Chem; 2018; 18(28):2420-2428. PubMed ID: 30526462
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive Characterization of HATs and HDACs in Human Cancers Reveals Their Role in Immune Checkpoint Blockade.
Sun R; Chen Z; Qu X; Zhang J; Liu L; Zhong Z; Zhang W; Fan Y
Crit Rev Eukaryot Gene Expr; 2024; 34(1):41-53. PubMed ID: 37824391
[TBL] [Abstract][Full Text] [Related]
24. HDAC inhibitor-based therapies: can we interpret the code?
New M; Olzscha H; La Thangue NB
Mol Oncol; 2012 Dec; 6(6):637-56. PubMed ID: 23141799
[TBL] [Abstract][Full Text] [Related]
25. The role dietary of bioactive compounds on the regulation of histone acetylases and deacetylases: a review.
Vahid F; Zand H; Nosrat-Mirshekarlou E; Najafi R; Hekmatdoost A
Gene; 2015 May; 562(1):8-15. PubMed ID: 25701602
[TBL] [Abstract][Full Text] [Related]
26. Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells.
Fortson WS; Kayarthodi S; Fujimura Y; Xu H; Matthews R; Grizzle WE; Rao VN; Bhat GK; Reddy ES
Int J Oncol; 2011 Jul; 39(1):111-9. PubMed ID: 21519790
[TBL] [Abstract][Full Text] [Related]
27. Diversity, evolution and expression profiles of histone acetyltransferases and deacetylases in oomycetes.
Wang XW; Guo LY; Han M; Shan K
BMC Genomics; 2016 Nov; 17(1):927. PubMed ID: 27852223
[TBL] [Abstract][Full Text] [Related]
28. Exploring the role of histone deacetylase inhibitors in cancer development and therapeutic potential.
Zhang C; Li HX; Man Y; Jiang ZH; Yin P; Yu K
J Physiol Pharmacol; 2024 Apr; 75(2):117-122. PubMed ID: 38736259
[TBL] [Abstract][Full Text] [Related]
29. Small molecule inhibitors of histone acetyltransferases and deacetylases are potential drugs for inflammatory diseases.
Dekker FJ; van den Bosch T; Martin NI
Drug Discov Today; 2014 May; 19(5):654-60. PubMed ID: 24269836
[TBL] [Abstract][Full Text] [Related]
30. Histone deacetylases in cardiac fibrosis: current perspectives for therapy.
Tao H; Shi KH; Yang JJ; Huang C; Zhan HY; Li J
Cell Signal; 2014 Mar; 26(3):521-7. PubMed ID: 24321371
[TBL] [Abstract][Full Text] [Related]
31. [Histone deacetylase inhibitors as therapeutic agents for polyglutamine disorders].
Jiang H; Jia D; Tang B
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Feb; 27(1):52-5. PubMed ID: 20140868
[TBL] [Abstract][Full Text] [Related]
32. Acetylation of proteins as novel target for antitumor therapy: review article.
Di Gennaro E; Bruzzese F; Caraglia M; Abruzzese A; Budillon A
Amino Acids; 2004 Jul; 26(4):435-41. PubMed ID: 15290351
[TBL] [Abstract][Full Text] [Related]
33. Fatty acids as histone deacetylase inhibitors: Old biochemistry tales in a new life sciences town.
Ediriweera MK
Drug Discov Today; 2023 May; 28(5):103569. PubMed ID: 36990144
[TBL] [Abstract][Full Text] [Related]
34. An Overview of HDAC Inhibitors and their Synthetic Routes.
Peng X; Liao G; Sun P; Yu Z; Chen J
Curr Top Med Chem; 2019; 19(12):1005-1040. PubMed ID: 30827245
[TBL] [Abstract][Full Text] [Related]
35. HDAC modulation and cell death in the clinic.
Dell'Aversana C; Lepore I; Altucci L
Exp Cell Res; 2012 Jul; 318(11):1229-44. PubMed ID: 22336671
[TBL] [Abstract][Full Text] [Related]
36. Targeting Class I Histone Deacetylases in Human Uterine Leiomyosarcoma.
Yang Q; Falahati A; Khosh A; Mohammed H; Kang W; Corachán A; Bariani MV; Boyer TG; Al-Hendy A
Cells; 2022 Nov; 11(23):. PubMed ID: 36497061
[TBL] [Abstract][Full Text] [Related]
37. Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis.
Shankar S; Srivastava RK
Adv Exp Med Biol; 2008; 615():261-98. PubMed ID: 18437899
[TBL] [Abstract][Full Text] [Related]
38. [Inhibition of Histone Deacetylases Reverses Epithelial-Mesenchymal Transition in Triple-Negative Breast Cancer Cells through a Slug Mediated Mechanism].
Rahimian A; Barati G; Mehrandish R; Mellati AA
Mol Biol (Mosk); 2018; 52(3):474-481. PubMed ID: 29989579
[TBL] [Abstract][Full Text] [Related]
39. Alcohol-induced serotonergic modulation: the role of histone deacetylases.
Agudelo M; Yoo C; Nair MP
Alcohol; 2012 Nov; 46(7):635-42. PubMed ID: 22796363
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia.
Ceccacci E; Minucci S
Br J Cancer; 2016 Mar; 114(6):605-11. PubMed ID: 26908329
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
